Tilmanocept
Sponsors
Universitair Medisch Centrum Utrecht, University of California, San Diego, Navidea Biopharmaceuticals, University Hospital, Ghent
Conditions
Arthritis, RheumatoidBreast CancerCarcinoma of the parotid glandEndometrial cancerOral cancerRheumatoid ArthritisSentinel Lymph Nodeuterine cancer
Phase 1
Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging
CompletedNCT02683421
Start: 2016-07-31End: 2016-12-31Updated: 2019-11-21
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
WithdrawnNCT03241446
Start: 2017-09-30End: 2018-03-31Updated: 2018-10-09
Phase 3
Sentinel lymph node biopsy in patients with parotid gland carcinoma using a combination of 99mTc-nanocolloid and 68Ga-tilmanocept PET/CT: A feasibility study. (SNparotis)
Not yet recruitingCTIS2024-514233-37-00
Target: 10Updated: 2024-07-12
SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high- intermediate risk endometrial cancer: a proof-of-concept study
Not yet recruitingCTIS2024-516708-40-00
Target: 10Updated: 2024-11-15
Sentinel lymph node (SLN) detection in early oral cancer using Gallium-68-Tilmanocept PET/CT.
SuspendedCTIS2025-521682-27-00
Target: 94Updated: 2025-04-18